COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF PAEDIATRIC PATIENTS WITH SYSTEMIC CANDIDA INFECTIONS

被引：0
|
作者：
Odeyemi, A. [1 ]
Hart, W. M. [1 ]
Odeyemi, I. I. [2 ]
Musingarimi, P. [3 ]
机构：
[1] EcoStat Consulting Ltd, London, England
[2] Astellas Pharma Europe Ltd, Middlesex, England
[3] Astellas Pharma Europe Ltd, Staines, England
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72923-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A189 / A189
页数：1
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN FOR TREATMENT OF SYSTEMIC CANDIDA INFECTIONS IN ITALY
    Sidhu, M. K.
    Van Engen, A. K.
    Switjnk, A. B.
    Concia, E.
    VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
  • [2] Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK
    Sidhu, M. K.
    van Engen, A. K.
    Kleintjens, J.
    Schoeman, O.
    Palazzo, M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (08) : 2049 - 2059
  • [3] MICAFUNGIN VERSUS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR SWITZERLAND
    Felder, S.
    Mayrhofer, T.
    VALUE IN HEALTH, 2014, 17 (03) : A275 - A275
  • [4] MICAFUNGIN VS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR GERMANY
    Felder, S.
    Grabe, K.
    Mayrhofer, T.
    Decker, S.
    VALUE IN HEALTH, 2009, 12 (07) : A426 - A427
  • [5] Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses
    Mistro, Sostenes
    Rosa, Lorena
    Gomes, Barbara
    Miranda, Ligia
    Badaro, Roberto
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (04) : 465 - 473
  • [6] Cost-effectiveness of amphotericin B formulations in the treatment of systemic fungal infections
    Lobo Borba, Helena Hiemisch
    Steimbach, Laiza Maria
    Riveros, Bruno Salgado
    Tonin, Fernanda Stumpf
    Ferreira, Vinicius Lins
    de Queiros Bagatim, Bruna Aline
    Balan, Gisele
    Pontarolo, Roberto
    Wiens, Astrid
    MYCOSES, 2018, 61 (10) : 754 - 763
  • [7] COST-EFFECTIVENESS ANALYSIS OF EMPIRIC LIPOSOMAL AMPHOTERICIN B VERSUS VORICONAZOLE IN TURKEY
    Turner, S. J.
    Senol, E.
    Kara, A.
    Al-Badriyeh, D.
    Kong, D. C.
    Dinleyici, E. C.
    VALUE IN HEALTH, 2013, 16 (07) : A356 - A356
  • [8] Micafungin versus liposomal amphotericin B (AmBisome®) in paediatric patients with invasive candidiasis or candidaemia
    Arrieta, A.
    Queiroz-Telles, F.
    Berezin, E.
    Freire, A.
    Diekmann, S.
    Koblinger, S.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S28 - S28
  • [9] COST-EFFECTIVENESS ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN IN THE TREATMENT OF INVASIVE CANDIDA INFECTION IN CHINA
    Wang, C.
    Dong, H.
    Sun, L.
    VALUE IN HEALTH, 2014, 17 (03) : A275 - A276
  • [10] Cost-effectiveness of liposomal amphotericin B treatments for paediatric visceral Leishmaniasis in Morocco
    Alonso, A.
    Tachfouti, N.
    Najdi, A.
    Sicuri, E.
    Picado, A.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 : 184 - 184
12345